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Brief Definit ive Report
Chemokines are chemotactic cytokines that 
guide the directed migration of leukocytes in 
the steady-state and in inflammation through a 
subfamily of seven-transmembrane spanning G 
protein–coupled receptors. The CC chemokine 
ligand (CCL) 18 was identified in the late 1990s 
by several groups as a gene highly expressed in 
the lung and induced in alternatively activated 
macrophages (AAMs) and thus initially given 
the names PARC (pulmonary and activation-
regulated chemokine), AMAC-1 (alternative 
macrophage activation-associated CC chemo-
kine-1), DC-CK1 (dendritic cell chemokine 1), 
and macrophage inflammatory protein (MIP) 4 
(Adema et al., 1997; Hieshima et al., 1997; 
Kodelja et al., 1998). CCL18 is highly expressed 
in many human chronic inflammatory diseases, 
which include pulmonary fibrosis and certain 
cancers, and a wide range of allergic diseases 
(Pivarcsi et al., 2004; Schutyser et al., 2005; 
de Nadaï et al., 2006; Chen et al., 2011; Lucendo 
et al., 2011). In some diseases, the level of circu-
lating CCL18 has been demonstrated to be a 
biomarker for disease activity and outcome 
(Prasse et al., 2009). In patients with systemic 
sclerosis, for instance, levels of CCL18 have 
been associated with the complication of inter-
stitial lung disease, and in patients with idio-
pathic pulmonary fibrosis and certain cancers, 
levels of CCL18 have been correlated with 
poor outcomes (Prasse et al., 2007, 2009; Chen 
et al., 2011). Understanding the role of CCL18 
in these diseases has been hampered by the lack 
of an identified receptor and by the lack of a 
known murine orthologue.
CCL18 is secreted primarily by cells of 
the myeloid lineage and has been identified 
in alveolar macrophages, tolerogenic dendritic 
cells, AAMs, and keratinocytes (Hieshima et al., 
1997; Kodelja et al., 1998; Pivarcsi et al., 2004; 
Bellinghausen et al., 2012). In macrophages, 
CCL18 is induced by the Th2 cytokines IL-4 
and IL-13, which program macrophages to 
differentiate into AAMs (Kodelja et al., 1998). 
AAMs contribute to the healing phase of acute 
CORRESPONDENCE  
Andrew D. Luster:  
aluster@mgh.harvard.edu
Abbreviations used: AAM, 
alternatively activated macro-
phage; CCL, CC chemokine 
ligand; EoE, eosinophilic 
esophagitis; MCP, monocyte 
chemoattractant protein; MIP, 
macrophage inflammatory 
protein; PTX, pertussis toxin; 
vMIP, viral MIP.
S.A. Islam and M.F. Ling contributed equally to this paper.
Identification of human CCR8  
as a CCL18 receptor
Sabina A. Islam, Morris F. Ling, John Leung, Wayne G. Shreffler,  
and Andrew D. Luster
Center for Immunology and Inflammatory Diseases, Division of Rheumatology, Allergy and Immunology,  
Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114
The CC chemokine ligand 18 (CCL18) is one of the most highly expressed chemokines in 
human chronic inflammatory diseases. An appreciation of the role of CCL18 in these dis-
eases has been hampered by the lack of an identified chemokine receptor. We report that 
the human chemokine receptor CCR8 is a CCL18 receptor. CCL18 induced chemotaxis and 
calcium flux of human CCR8-transfected cells. CCL18 bound with high affinity to CCR8 
and induced its internalization. Human CCL1, the known endogenous CCR8 ligand, and 
CCL18 competed for binding to CCR8-transfected cells. Further, CCL1 and CCL18 induced 
heterologous cross-desensitization of CCR8-transfected cells and human Th2 cells. CCL18 
induced chemotaxis and calcium flux of human activated highly polarized Th2 cells through 
CCR8. Wild-type but not Ccr8-deficient activated mouse Th2 cells migrated in response to 
CCL18. CCL18 and CCR8 were coexpressed in esophageal biopsy tissue from individuals 
with active eosinophilic esophagitis (EoE) and were present at markedly higher levels 
compared with esophageal tissue isolated from EoE patients whose disease was in remission 
or in normal controls. Identifying CCR8 as a chemokine receptor for CCL18 will help clarify 
the biological role of this highly expressed chemokine in human disease.
© 2013 Islam et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
T
h
e 
Jo
u
rn
al
 o
f 
E
xp
er
im
en
ta
l 
M
ed
ic
in
e
1890 CCR8 is a CCL18 receptor | Islam et al.
also induced a peak migration of CCR8 transfectants at 10 nM 
but with a more robust response (Fig. 1 b). CCL18-induced 
chemotaxis in CCR8-transfected cells was inhibited by per-
tussis toxin (PTX), indicating that CCL18 induced the spe-
cific coupling of CCR8 to Gi (Fig. 1 c). Checkerboard-type 
chemotaxis analysis revealed that CCL18 stimulated chemo-
taxis rather than chemokinesis (Fig. 1 d). CCL18 did not an-
tagonize chemotaxis of CCR8-transfected cells to CCL1 when 
both chemokines were present in the bottom chamber in tran-
swell chemotaxis assays (Fig. 1 e).
CCL18 induced calcium flux in CCR8-transfected cells
CCR8 transfectants showed a rapid and robust dose-dependent 
increase in intracellular calcium upon stimulation with CCL18 
(Fig. 2 a). In control experiments, CCL18 did not induce a 
calcium flux in untransfected 4DE4 cells, although they re-
sponded to CXCL12 with a robust calcium flux (Fig. 2 b). 
Heterologous desensitization of ligand-induced calcium flux 
is routinely used to assess activity at a shared receptor. 
Stimulation of CCR8 transfectants with CCL18 inhibited, 
albeit incompletely, subsequent signaling to CCL1, reflecting 
inflammatory reactions and to tissue remodeling and fibrosis 
in chronic inflammatory diseases. Concordant with the spec-
trum of AAM activity, the abundance of CCL18 has been 
found to correlate with disease severity in fibrotic diseases, 
such as pulmonary fibrosis and scleroderma, and diseases of 
dysregulated macrophage biology (Schutyser et al., 2005; 
Prasse et al., 2007, 2009). In allergic diseases, increased CCL18 
is also frequently associated with eosinophil infiltration in 
affected tissues (Pivarcsi et al., 2004; Schutyser et al., 2005; 
de Nadaï et al., 2006; Lucendo et al., 2011).
CCL18 activity has been detected on peripheral blood 
lymphocytes (Adema et al., 1997; Hieshima et al., 1997). How-
ever, studies using cells transfected with CCR1-7, CXCR1-4, 
and CX3CR1 did not reveal a specific CCL18 signaling re-
ceptor but did find that CCL18 could antagonize CCR3 
(Hieshima et al., 1997; Nibbs et al., 2000). Investigation into 
atopic dermatitis and allergic diseases enabled the first identi-
fication of a specific T cell subset that responded to CCL18, 
and thus provided clues to its possible chemokine receptor 
(Günther et al., 2005; de Nadaï et al., 2006). In atopic derma-
titis, CCL18 is the most abundantly expressed chemokine 
in lesional skin (Pivarcsi et al., 2004; Günther et al., 2005). 
CCL18 bound to blood skin-tropic cutaneous leukocyte 
antigen expressing (CLA+) memory T cells from individuals 
with atopic dermatitis and induced migration of CD4+ T cell 
clones derived from atopic dermatitis lesional skin in vitro and 
into human skin transplanted in SCID mice in vivo (Günther 
et al., 2005). The signature homing receptors of skin-tropic 
T cells are CLA in combination with the chemokine receptors 
CCR4, CCR10, and CCR8 (Schaerli et al., 2004; Islam et al., 
2011). More CCR8-expressing cells are found in inflamed 
skin of individuals with active atopic dermatitis compared with 
skin of healthy individuals (Gombert et al., 2005). In studies 
of human asthma, CCL18 was found to induce the migration 
of TCR-activated in vitro differentiated human Th2 cells 
(de Nadaï et al., 2006). CCL18 induced migration of human 
peripheral blood Th2 cells and regulatory T cells ex vivo 
(Bellinghausen et al., 2012; Chenivesse et al., 2012). Th2 but 
not Th1 cells are programmed to selectively express the che-
mokine receptors CCR4 and CCR8, a receptor profile shared 
with regulatory T cells (D’Ambrosio et al., 1998; Wei et al., 
2010). Skin-homing CLA+ T cells, Th2 cells, and regulatory 
T cells thus all express CCR4 and CCR8. However, TCR 
activation is a prerequisite for functional CCR8 but not CCR4 
expression on in vitro differentiated Th2 cells (D’Ambrosio 
et al., 1998). Here, we report that CCL18 is an endogenous 
agonist of the human CCR8 receptor.
RESULTS AND DISCUSSION
CCL18 induced migration of CCR8-transfected cells
We assayed the ability of 4DE4 mouse pre–B cell lines trans-
fected with human CCR8 to chemotax to CCL18 and ob-
served peak migration at 10 nM (Fig. 1 a). Untransfected 
4DE4 cells exhibited migration to CXCL12 (not depicted), 
but not to CCL18 (Fig. 1 a) or the known human CCR8 
chemokine agonist CCL1 (also called I-309; Fig. 1 b). CCL1 
Figure 1. CCR8 is sufficient for CCL18-induced migration. (a and b)  
Dose–response chemotaxis of hCCR8-transfected and untransfected  
4DE4 cells to CCL18 (a) and hCCL1 (b). (c) Chemotaxis of PTX treated 
hCCR8-transfected cells to CCL18 (*, P < 0.05 by unpaired two-tailed t test  
in a–c). (d) Chemotaxis of hCCR8-transfected 4DE4 cells in a checker-
board-type transwell chemotaxis assay with varying concentrations  
of CCL18 in the bottom and top chamber. (e) Chemotaxis of hCCR8- 
transfected 4DE4 cells to varying concentrations of CCL1 mixed with 
varying concentrations of CCL18 in the bottom chamber (P = NS for 
CCL18 by two-way ANOVA). Data in all panels are representative of at 
least three independent experiments (mean ± SEM).
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cells at 4°C did not affect mAb binding to CCR8. To demon-
strate that CCL18 induced CCR8 internalization, we fol-
lowed the kinetics of surface, total, and internalized (total  
surface) CCR8 levels in CCR8-transfected cells after treatment 
with CCL18 or CCL1 (108 M). After treatment with CCL18 
or CCL1, surface CCR8 levels decreased contemporaneously 
with increased internalized CCR8 levels, whereas total CCR8 
levels were not affected by either treatment (Fig. 3 c).
CCL18 binds to CCR8
Competitive ligand binding experiments with 125I-labeled 
CCL18 and 125I-labeled hCCL1 enabled us to determine specific 
CCL18-induced partial desensitization of the CCR8 re-
ceptor (Fig. 2 c). Stimulation of CCR8 transfectants with 
CCL1 completely inhibited subsequent signaling to CCL18 
(Fig. 2 c). We then assayed the ability of CCL18 to desensitize 
another well characterized agonist of the human CCR8 re-
ceptor, HHV-8 (human herpes virus 8)–encoded chemokine 
viral MIP (vMIP) 1 (Dairaghi et al., 1999). vMIP-1–induced 
calcium signaling was partially desensitized by CCL18, and 
vMIP-I completely desensitized CCL18-induced signaling 
(Fig. 2 d). We also assayed the L1.2 murine pre–B cell line 
stably transfected with human CCR8 for chemotaxis and cal-
cium flux to CCL18 but found that they responded weakly 
to CCL18 despite responding to CCL1. We do not have a 
clear explanation for the discrepancy in the magnitude of 
CCL18 responsiveness between L1.2 and 4DE4 CCR8 trans-
fectants but consequently pursued all our functional studies 
on 4DE4 CCR8 transfectants.
CCL18 promoted internalization of CCR8
Chemokine receptors typically undergo internalization upon 
chemokine agonist binding. Robust surface expression of CCR8 
on CCR8-transfected cells was detected at baseline but not 
on untransfected 4DE4 cells (Fig. 3 a). Surface CCR8 expres-
sion on CCR8-transfected cells was reduced after treatment 
with increasing concentrations of CCL18 or CCL1 but not 
CCL17 (a CCR4 but not CCR8 agonist) for 20 min at 37°C 
(Fig. 3 b). CCL18 and CCL1 binding to CCR8-transfected 
Figure 2. CCL18 induces calcium flux in CCR8-transfected cells. 
(a) Dose–response calcium flux of hCCR8-transfected cells to CCL18.  
(b) Calcium flux of untransfected 4DE4 cells to CCL18 and CXCL12.  
(c and d) Heterologous cross-desensitization of hCCR8-transfected cells 
to CCL18 and CCL1 (c), and to CCL18 and vMIP-I (d). a–d are representa-
tive of three to eight independent experiments. Figure 3. CCL18 induces internalization of CCR8 and inhibits  
125I-CCL18 and 125I-hCCL1 binding to CCR8. (a) Representative FACS  
plots of CCR8 surface expression on hCCR8-transfected and untrans-
fected cells. (b) Dose-dependent internalization of surface CCR8 in hCCR8- 
transfected cells stimulated with CCL18 and hCCL1 but not CCL17 (*, P < 0.05; 
**, P = 0.06, for CCL18 vs. CCL17 and CCL1 vs. CCL17 by unpaired two-
tailed t test). (c) Kinetics of internalized versus surface CCR8 expression in 
hCCR8-transfected cells stimulated with CCL18 (108 M) or hCCL1 (108 M) 
for 1, 5, 10, or 20 min at 37°C (*, P < 0.05 for internalized or surface CCR8 
treated with CCL18 or CCL1 at 37°C compared with 4°C control by un-
paired two-tailed Student’s t test). Data are expressed as mean ± SEM, 
representative of at least five experiments in a–c. (d) Inhibition of 0.2 nM 
125I-CCL18 binding to hCCR8-transfected cells with increasing concentra-
tions of unlabeled CCL18 and hCCL1. Representative of two (cold hCCL1) 
and five (cold CCL18) experiments (P = 0.01 for CCL18 versus CCL3 and  
P ≤ 0.0001 for CCL1 versus CCL3 by two-way ANOVA). (e) Inhibition of  
0.1 nM 125I-hCCL1 binding to hCCR8-transfected cells with unlabeled CCL18 
and hCCL1. Representatives of three (cold hCCL1) and five (cold CCL18) 
experiments are shown; data are shown as mean ± SEM in d and e.
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CCL18 induced migration and calcium flux  
of highly polarized Th2 cells
CCR8 induction in murine Th2 cells at levels high enough 
to detect agonist function occurs transiently after TCR ac-
tivation of Th2 cells generated by multiple rounds of polar-
ization (D’Ambrosio et al., 1998; Islam et al., 2011). Human 
Th2 cells also exhibited increased CCR8 expression with 
successive rounds of Th2 polarization (Fig. 4 a) with a con-
comitant increase in IL-4 and IL-5 expression (Fig. 4 b). 
Highly polarized human Th2 cells generated by three rounds 
of polarization with subsequent TCR activation (Th2 R3) 
migrated in response to CCL18 and CCL1, whereas less 
polarized Th2 cells that expressed lower levels of CCR8 did 
not (Fig. 4 c). Peak migration for both CCL18 and CCL1 
was at 10 nM, similar to what was observed on CCR8-
transfected cells. CCL18-induced chemotaxis of Th2 R3 
high affinity binding of CCL18 to CCR8. In direct competi-
tion binding experiments, CCL18 competed for 125I-CCL18 
binding to CCR8-transfected cells with a Ki of 1.04 nM, 
whereas human CCL1 competed for 125I-CCL18 binding with 
a Ki of 0.09 nM (Fig. 3 d). In heterologous cross-competition 
binding experiments, CCL18 competed for 125I-CCL1 bind-
ing to CCR8 with a Ki of 1.89 nM, and CCL1 competed for 
125I-CCL1 binding with a Ki of 0.114 nM, which is consis-
tent with published CCL1 Ki values (Fig. 3 e). hCCL3, the 
human chemokine with the greatest homology to CCL18, 
did not compete for either 125I-CCL18 or 125I-hCCL1 bind-
ing to CCR8 (not depicted). The Ki determined for CCL18 
is comparable to the published Kd of 1.9 nM measured on 
lymphocytes in saturation binding experiments and also to 
the Ki values determined for vMIP-I (Hieshima et al., 1997; 
Dairaghi et al., 1999).
Figure 4. CCL18 induces calcium flux and CCR8-
dependent migration of activated highly polarized 
Th2 cells. (a) Representative histograms of CCR8 expres-
sion on human Th2 cells that have undergone one (Th2 R1),  
two (Th2 R2), or three (Th2 R3) rounds of Th2 polari-
zation. (Left) CCR8 mAb staining and isotype control are 
depicted with colored and gray lines, respectively. (Right) 
Quantitation of CCR8 surface expression on human Th2 
cells. (*, P < 0.05 for CCR8 on Th2 R1 vs. Th2 R3 by un-
paired two-tailed Student’s t test). (b) Representative 
cytokine profiles of Th2 cells. (c) Dose–response chemo-
taxis of activated human Th2 cells to CCL18 (left) or 
hCCL1 (right; *, P < 0.05 for Th2 R1 vs. Th2 R3 by un-
paired two-tailed Student’s t test). (d) Comparison of 
chemotaxis of 100 ng/ml PTX–treated activated human 
Th2 R3 cells and untreated controls. (e) Activated human 
Th2 R3 cells were treated with 1 µg/ml CCR8 mAb and 
compared with untreated activated Th2 R3 cells in che-
motaxis assay to CCL18. a–e are representative of at least 
three independent experiments (mean ± SEM). (f) Dose-
dependent calcium flux response of human Th2 R3 cells 
to CCL18 stimulation. (g) Heterologous cross-desensitiza-
tion of the calcium flux response of human Th2 R3 cells 
to CCL18 and hCCL1 stimulation. f and g are representa-
tive of three to five separate experiments. (h) Representa-
tive histograms of surface expression of the LFA-1 
activation epitope m24 on activated human Th2 R3 cells 
treated with CCL18, CXCL12, PMA, or not treated (left). 
Quantitation of m24 expression on activated Th2 R3 cells 
after CCL18 or CXCL12 stimulation (right). (i) Chemotaxis 
of activated wild-type and Ccr8-deficient mouse Th2 cells 
to CCL18. (j) Chemotaxis of mCcr8-transfected and un-
transfected Baf/3 cells to CCL18 stimulation. h–j are rep-
resentative of at least three independent experiments 
(mean ± SEM; *, P < 0.05 by unpaired two-tailed Stu-
dent’s t test for d, e, and h–j).
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CCL18 activates mouse CCR8
Activated highly differentiated wild-type mouse Th2 cells 
migrated to CCL18 in a dose-dependent bell-shaped migra-
tion curve with peak migration at 1 nM (Fig. 4 i). Migration 
was abrogated in Ccr8-deficient Th2 cells in which migra-
tion to the positive control CXCL12 remained intact and com-
parable to wild-type Th2 cells (not depicted). Moreover, 
mCcr8-transfected but not untransfected Baf/3 murine B cells 
migrated in response to CCL18 with peak migration at 10 nM 
(Fig. 4 j). The peak migration induced by CCL18 was com-
parable to the peak migration induced in these cells by mCCL1 
and the recently identified second chemokine ligand for murine 
CCR8, mouse CCL8 (mCCL8 or mouse monocyte chemo-
attractant protein [MCP] 2; Islam et al., 2011).
Human CCL18 and murine CCL8 are functional analogues
Although mCCL8 was originally given the orthologous desig-
nation to human CCL8 (hCCL8), we recently established they 
are not functional orthologues. hCCL8 is not a CCR8 ligand 
but is a CCR2 ligand, whereas mCCL8 is a CCR8 ligand but 
cells was inhibited by PTX (Fig. 4 d). A blocking mAb to 
human CCR8 specifically inhibited migration of Th2 R3 
cells to CCL18 (Fig. 4 e). Th2 R3 cells also showed robust 
calcium flux to CCL18 in a dose-dependent manner (Fig. 4 f ). 
Stimulation of highly polarized Th2 cells with CCL18 inhib-
ited subsequent signaling to CCL1, and CCL18-induced 
calcium signaling in Th2 cells was desensitized by CCL1 sig-
naling (Fig. 4 g).
CCL18 induced LFA-1 activation
Chemokine signaling can induce “inside-out” activation of 
integrins. In T cells, chemokine activation of LFA-1 results 
in a conformational change that can be detected by mAb24, 
which recognizes the appearance of a new LFA-1 epitope 
m24 (Schürpf and Springer, 2011). CCL18 induced expres-
sion of the m24 epitope, detected by mAb24, which was 
comparable to that induced by CXCL12 or PMA on acti-
vated highly polarized Th2 cells at 37°C. This increase in 
mAb24 binding was not detected at 4°C or in the absence of 
stimulation (Fig. 4 h).
Figure 5. CCL18 expression in AAM and in 
human EoE. (a) Induction of CCL18 and CCL17 RNA 
in human AAM by IL-4 at 24 h. (b) Comparison of 
24- and 72-h CCL18 and CCL17 induction in human 
AAM after IL-4, IL-10, and TNF treatment. (c) 24-h 
induction of Ccl8 and Ccl17 in mouse AAM by IL-4.  
(d) Comparison of 24 and 72 h Ccl8 and Ccl17  
induction in mouse AAM after treatment with IL-4, 
IL-10, and TNF. a–d are representative of at least 
three independent experiments (mean ± SEM; *, P < 
0.05 by unpaired two-tailed Student’s t test for a–d). 
(e) Expression of CCL18 and CCR8 and other Th2-
associated chemokines (top) and receptors (bottom) 
in esophageal biopsy tissue recovered from indi-
viduals with active EoE (A), individuals with EoE in 
remission (R), and normal controls (N). Data are 
presented in box-and-whiskers plots with bars indi-
cating fifth and 95th percentiles (*, P < 0.05 by 
Mann-Whitney test). (f) Relationship of CCR8 mRNA 
expression to the expression of CCL1 (blue square), 
CCL18 (green circle), and CCL26 (red diamond) in the 
human esophageal samples from all groups studied 
(r represents Spearman correlation).
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with active EoE compared with subjects whose disease was in 
remission and to normal controls (Fig. 5 e). CCL1, CCL26, 
CCR3, and CRTH2 mRNA were also up-regulated in active 
EoE. Moreover, CCL18 and CCL1 mRNA levels in esopha-
geal tissue correlated strongly with CCR8 mRNA levels 
(Fig. 5 f). In contrast, the eosinophil chemoattractant CCL26, 
which is known to be abundantly expressed in EoE (Blanchard 
et al., 2007) and is a CCR3 ligand, was not as highly corre-
lated with CCR8 (Fig. 5 f). Thus, CCL18 and its receptor 
CCR8 are coexpressed in human diseased tissue during active 
eosinophilic inflammation, consistent with our findings in 
the mouse.
Phylogeny of CCL18
CCL18 has orthologues only in primates (Homologene). Se-
quence analysis revealed that CCL18 shares the most amino 
acid identity (65%) with hCCL3 (MIP-1), which lacks ac-
tivity on CCR8. It is hypothesized that the CCL18 gene, 
which is located within the MIP chemokine gene cluster, 
arose through duplication and fusion of two CCL3-like genes 
with deletion and selective use of exons after the speciation of 
primates and rodents (Schutyser et al., 2005). Consistent with 
this hypothesis, vMIP-1, the potent virally encoded CCR8 
agonist also believed to have arisen from the MIP gene clus-
ter, is more homologous to CCL18 (46% identity) than it is 
to the other CCR8 agonist hCCL1 (25% identity). Align-
ment of the mature amino acid sequences of the CCR8 ago-
nists CCL18, CCL1, and vMIP-1 revealed that only CCL18 
and vMIP-I share a continuous stretch of 20-aa identity. The 
human and mouse MIP and MCP chemokines are closely 
linked gene clusters on human chromosome 17 and mouse 
chromosome 11. Inflammatory cluster chemokines often tend 
to evolve rapidly, and tandem gene duplication and diversifi-
cation are believed to have occurred within the MCP and MIP 
clusters independently after the speciation of rodents and pri-
mates (Zlotnik and Yoshie, 2012). This may explain why these 
two chemokine clusters are not orthologous between humans 
and mice and why mouse CCL8 and human CCL18 lack 
identified orthologues by phylogenetic analysis and synteny 
mapping. Instead, functional analogues need to be identified 
based on similar biological function, such as similar regula-
tion and receptor usage, as we have demonstrated for human 
CCL18 and mouse CCL8.
Our study shows that CCR8 has two endogenous che-
mokine ligands. Ligands for the same chemokine receptor 
often have distinct yet cooperative and complementary func-
tions in vivo (Zlotnik and Yoshie, 2012). In the CCR8 system, 
CCL1 appears to be the more potent agonist. However, 
CCL18 appears to be more highly expressed in inflammation. 
CCL18 is detected at two log higher levels than CCL1 in le-
sional atopic skin, which is analogous to the two log higher 
expression of mCCL8 compared with mCCL1 in inflamed 
atopic mouse skin (Pivarcsi et al., 2004; Gombert et al., 2005; 
Islam et al., 2011). While CCL18 is expressed in dermal den-
dritic cells and keratinocytes, CCL1 is expressed by epidermal 
Langerhans cells and skin endothelial cells (Gombert et al., 2005). 
is not a CCR2 ligand (Islam et al., 2011). Synteny mapping of 
mCCL8 and hCCL8, which are located in the mouse and 
human MCP chemokine clusters, respectively, has also re-
vealed they are not orthologues (Zlotnik and Yoshie, 2012). 
In fact, mCCL8 lacks a human orthologue, and both hCCL8 
and CCL18 lack rodent orthologues (Homologene, MGI).
This has led us to hypothesize that mCCL8 and CCL18 
may be functional analogues. Consistent with this hypothesis, 
CCL18 and mCCL8 have been reported to be highly in-
duced in AAMs (Kodelja et al., 1998; Schutyser et al., 2005; 
Thomas et al., 2012; Egawa et al., 2013). Additionally, mCCL8 
was the most abundant chemokine induced in the lung in a 
bleomycin model of pulmonary fibrosis by microarray analy-
sis (Liu et al., 2011), and CCL18 is the most highly expressed 
chemokine in idiopathic pulmonary fibrosis (Prasse et al., 2009).
We thus determined if cytokines known to regulate 
CCL18 induction might also regulate mCCL8 induction in 
AAMs in an analogous fashion. As expected, human CCL18 
and another human Th2-associated chemokine CCL17 were 
both induced in human AAMs in response to IL-4, but 
CCL18 was induced to much greater levels (Fig. 5 a). Con-
sistent with published studies (Kodelja et al., 1998), we found 
that IL-10 weakly induced CCL18 in macrophages. How-
ever, as noted by others, a combination of IL-4 and IL-10 
synergistically induced CCL18 (Pechkovsky et al., 2010), 
which is in distinct contrast to IL-4 and TNF (Fig. 5 b). In 
contrast, IL-10 treatment did not induce CCL17 and instead 
inhibited IL-4–induced CCL17 expression in AAMs, whereas 
TNF and IL-4 synergistically induced CCL17 (Fig. 5 b).
In mouse AAMs, we found that Ccl8 and Ccl17 were also 
induced by IL-4. AAM differentiation was confirmed by the 
specific induction of the mouse AAM markers Arg1, Ym1, 
and Fizz1 (Fig. 5 c). In a striking parallel to CCL18 induc-
tion in human AAMs, IL-4 and IL-10 both independently 
induced Ccl8, and importantly, IL-4 and IL-10 in combina-
tion, but not IL-4 and TNF, synergistically induced Ccl8 ex-
pression (Fig. 5 d). In contrast, regulation of Ccl17 induction 
in mouse AAMs mirrored that of human CCL17 in human 
AAMs and was distinct from that of CCL18 and Ccl8. Thus, 
IL-10, an inhibitory cytokine, paradoxically amplified IL-4 
induction of both Ccl8 and CCL18. These data provide evi-
dence that CCL18 and Ccl8 are regulated similarly in AAMs, 
which lends further support to the hypothesis that mCCL8 
and CCL18 are functional analogues.
CCL18 and CCR8 are induced in human  
eosinophilic inflammation
Previously, we found that CCR8 and mCCL8 were essential 
for the induction of chronic eosinophilic skin inflammation 
in vivo (Islam et al., 2011). To investigate whether CCL18 and 
its receptor CCR8 are involved in chronic human eosino-
philic inflammation, we examined esophageal biopsy tissue 
of patients with eosinophilic esophagitis (EoE; Table S1) for 
expression of Th2-associated chemokines (CCL18, CCL1, 
and CCL26) and receptors (CCR8, CCR3, and CRTH2). 
CCL18 and CCR8 mRNA were up-regulated in subjects 
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gastrointestinal symptoms suggestive of reflux or EoE (Table S1). Normal 
controls had a normal appearing esophagus on endoscopy and had no histo-
logical findings of inflammation on esophageal biopsy. In accordance with 
the consensus guidelines, active EoE was defined by the presence of >15 
eosinophils per 40× high power field (hpf) in at least one esophageal biopsy 
(of a total six obtained from the proximal, middle, and distal esophagus) de-
spite a minimum 6-wk course of high dose proton pump inhibitors (Liacouras 
et al., 2011). EoE patients in remission were on either elimination diet or on 
topical steroid treatment, and esophageal biopsy samples contained fewer 
than five eosinophils/hpf in all six biopsies. All human subject protocols 
were approved by the Partners Institutional Review Board. Informed con-
sent was obtained from all study participants.
Mice. C57BL/6 mice were purchased from the National Cancer Institute 
(Bethesda, MD). CCR8/ mice (from S. Lira, Mount Sinai School of Medi-
cine, New York) in the C57BL/6 background were housed under specific 
pathogen-free conditions. All protocols were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care.
Human and mouse CCR8 receptor–transfected cells. Limiting dilu-
tion clones were generated from a CCL18-responsive CCR8-transfected 
4DE4 cell line (provided by J. Pease, Imperial College, London, UK) grown 
in low concentrations of G418 (0.1–0.4 mg/ml; Tiffany et al., 1997). We 
found that these clones responded better to CCL18 when grown in low 
G418 concentrations (and, in fact, seemed to lose activity at G418 concentra-
tions ≥1 mg/ml) and were therefore maintained in 0.1 mg/ml G418. 4DE4 
cells were provided by P. Murphy (National Institutes of Health, Bethesda, 
MD). hCCR8-L1.2 transfected cell line was provided by M. Locati and A. 
Mantovani (University of Milan, Milan, Italy). Cells were treated with 5 mM 
butyric acid overnight in some calcium flux, binding, and chemotaxis assays 
to increase surface expression of CCR8. Mouse Ccr8-transfected Baf/3 cells 
were generated as previously described (Islam et al., 2011).
Generation of human monocyte-derived DCs. DCs were generated 
from PBMCs isolated from fresh human buffy coats by Histopaque-1077 
density gradient (Sigma-Aldrich). PBMCs were resuspended in C10 media 
(RPMI complete medium with 10% fetal calf serum) and incubated for 
2–3 h at 37°C and washed gently with PBS. The remaining adherent cells 
were cultured in 10 ml C10 media supplemented with 50 ng/ml of GM-CSF 
(BioLegend) and 50 ng/ml IL-4 (PeproTech) at 37°C. Additional GM-CSF 
and IL-4 was added on days 2, 4, and 5. On day 6, DCs were rested for 
24 h after change of media, and then incubated with C10 media containing 
100 ng/ml of LPS (Sigma-Aldrich) for 24–48 h.
Generation of Th2 cells and induction of highly polarized Th2 cells. 
CD4+ T cells were isolated from Histopaque-1077 density gradient PBMCs 
by two negative selection columns: (1) CD4+ T cell Biotin Antibody Cock-
tail (Miltenyi Biotec), followed by incubation with anti-biotin microbeads 
(Miltenyi Biotec) to isolate CD4+ T cells; and (2) CD45RO PE (BD) staining, 
followed by incubation with anti-PE microbeads to isolate naive (CD45RO) 
CD4+ T cells. DCs and T cells were cultured in C10 media with 50 ng/ml 
IL-4 and 10 µg/ml anti–IFN- (BioLegend) for 5 d at 37°C. At day 5, new 
C10 supplemented with 250 ng/ml IL-2 (Roche) was added. For repolariza-
tion of Th2 cells at day 7 to generate Th2 R2 cells, Th2 R1 cells were repo-
larized with irradiated human PBMCs, 1 µg/ml anti-CD3 (BioLegend), 
1 µg/ml anti-CD28 (BioLegend), 50 ng/ml IL-4, and 10 µg/ml anti–IFN- 
(BioLegend). A similar procedure was used to generate Th2 R3 cells from 
Th2 R2 cells. Prior to assays, Th2 cells were activated with 2 µg/ml plate-
bound mAb to CD3 and 1 µg/ml soluble mAb to CD28 for 24 h. Cells were 
then washed, replated, and rested for 4–6 h in low–IL-2 medium for migra-
tion or IL-2–free medium for calcium flux. Highly polarized and activated 
mouse Th2 cells were generated for chemotaxis assays in a similar manner as 
previously described (Islam et al., 2011).
Generation and activation of human and mouse macrophages. 
Human monocytes were isolated from peripheral blood by negative selection 
with the monocyte isolation kit II (Miltenyi Biotec) and differentiated into 
CCL1 may therefore promote entry through the cutaneous 
vasculature while CCL18 may promote retention of CCR8-
expressing cells in inflamed tissue. Thus, we predict that CCL1 
and CCL18 likely have nonredundant roles in vivo in part 
dictated by their pattern of expression and their activity on 
CCR8-expressing cells.
In certain human cancers (e.g., breast and ovarian), tumor-
associated macrophages, an AAM-like population which un-
dergoes additional differentiation by T reg cell–derived IL-10, 
abundantly produce CCL18 (Bonecchi et al., 2011). It is nota-
ble that the induction of both CCL18 and mCCL8 is markedly 
augmented by IL-10. In human breast cancer, CCL18 expres-
sion in blood and cancer stroma was associated with reduced 
patient survival (Chen et al., 2011). CCL18 promoted tumor cell 
invasiveness and metastasis, which was shown to be mediated 
by PITPNM3 (phosphatidylinositol transfer protein 3; Chen 
et al., 2011). PITPNM3 is a six-transmembrane receptor distinct 
from seven-transmembrane chemokine receptors (Bonecchi 
et al., 2011). We did not detect PITPNM3 RNA or protein 
expression in our CCR8-transfected 4DE4 B cell like cell lines 
or in Th2 R3 cells, although we did detect PITPNM3 RNA 
and protein in the MDA-MB-231 epithelial breast cancer cell 
line (unpublished data). Therefore, the CCL18-induced CCR8 
activation that we described in transfected cells and primary 
T cells was independent of PITPNM3.
Identifying CCR8 as a receptor for CCL18 offers new 
insights into the role of this important human chemokine 
identified in many chronic inflammatory diseases. In a recent 
transcription profiling study, CCR8 was found to be the che-
mokine receptor most highly expressed in induced T reg cells 
(Wei et al., 2010). Recruitment of CCR8-expressing T reg 
cells into an IL-10–rich tumor milieu may possibly explain 
the association of CCL18 with increased metastasis and poor 
prognosis. The ability of CCL18 to recruit CCR8-expressing 
Th2 cells may explain the association of this chemokine with 
many allergic diseases. Our data support this hypothesis by 
showing the coexpression of CCL18 and CCR8 in human 
diseased esophageal tissue in individuals with active EoE. This 
may also be of particular importance in atopic dermatitis 
where CCL18 is abundantly expressed and likely facilitates 
the recruitment of CCR8-expressing skin-homing Th2 cells, 
as we have seen for mCCL8 (Islam et al., 2011). Further, the 
attraction of Th2 cells by CCL18-secreting AAM may pro-
vide a positive-feedback loop for the maintenance of the AAM 
phenotype in chronic inflammation. These are a few examples 
in which understanding the receptor for CCL18 will allow a 
greater appreciation of its role in human disease. Identifying 
CCR8 as the CCL18 receptor and mCCL8 as its rodent 
functional analogue will also enable the study of the CCR8 
receptor–ligand system in murine disease models to better 
understand CCL18-mediated human disease pathology.
MATERIALS AND METHODS
Human studies. Peripheral blood was obtained from healthy volunteers, 
and fresh buffy coats were obtained from the Massachusetts General Hos-
pital blood bank. For endoscopy studies, patients were referred for upper 
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buffer before assays. Binding buffer consisted of 50 mM Hepes, 1 mM CaCl2, 
5 mM MgCl2, 0.5% BSA, and 125 mM NaCl, adjusted to a pH of 7.22 for 
competition binding experiments with 125I-hCCL1, and adjusted to a pH of 
7.4 with the addition of 0.05% sodium azide for competition binding experi-
ments with 125I-hCCL18. Cells were grown to log phase to a concentration 
of 1.2–1.7 million/ml at the time of the assay. Binding assays were performed 
for 1.5 h with continuous shaking at 140 rpm, and were performed at room 
temperature and at 37°c for experiments with 125I-hCCL1 and 125I-CCL18, 
respectively. At the end of the assay, plates were washed four times with 
ice-cold binding buffer. Radioactivity was counted after addition of scintil-
lation fluid in a TopCount NXT counter (Perkin-Elmer). 125I-hCCL1 and 
125I-CCL18 were purchased from Perkin-Elmer. Because CCL18 had been 
reported to self-aggregate at high concentrations (Hieshima et al., 1997), we 
adapted published binding protocols used for other chemokines also reported 
to self-aggregate, such as CCL5 and CCL3, to perform our direct competi-
tion binding experiments with 125I-CCL18. Binding data were analyzed 
with Prism 5 (GraphPad Software).
Internalization assays. Flow cytometry using the 433H CCR8 mAb was 
used to evaluate CCR8 receptor internalization. 5 × 106 cells CCR8-transfected 
4DE4 cells were resuspended in 100 µl of ice-cold culture medium in dupli-
cate, followed by addition of varying concentrations of CCL18, hCCL1, or 
hCCL17 (R&D Systems). One sample was incubated for 20 min at 37°C, 
whereas the other was kept at 4°C before washing, staining, and receptor 
expression analysis by flow cytometry. Receptor expression was calculated 
using the following equation: 100 × [(mean fluorescence of chemokine treated 
cells at 37°C  mean fluorescence of negative control cells)/(mean fluores-
cence of chemokine treated cells at 4°C  mean fluorescence of negative 
control cells)], where negative control cells were buffer-treated cells. To de-
termine the kinetics of surface and total CCR8 expression, 5 × 106 cells were 
resuspended in 100 µl of ice-cold culture medium in duplicate, followed by 
the addition of 108 M CCL18, 108 M CCL1, or media at 37 or 4°C). One 
set of samples was directly stained for CCR8 (surface CCR8), whereas the 
other was fixed and permeabilized and stained for CCR8 (total CCR8). The 
difference between total and surface CCR8 was defined as internalized 
CCR8. Change in expression of CCR8 is shown as the ratio of mean fluor-
escence (mean fluorescence of CCR8 + ligand/mean fluorescence of nega-
tive control). As controls, no significant internalization was seen when 
CCR8-transfected cells were stimulated with CCL18 and hCCL1 at 4°C or 
in cells incubated with media at 37°C.
RNA extraction and RT-PCR analysis for esophageal specimens 
and macrophages. Total RNA was extracted from cryopreserved esopha-
geal biopsy samples using mirVana Isolation Kit (P/N: 1560; Ambion) 
according to the manufacturer’s protocol. Power SYBR green qRT-PCR 
assay (Applied Biosystems) was used for mRNA quantification using 
StepOnePlus Real-Time PCR System (Applied Biosystems). The following 
primers were used: CCL26, 5-CCAAGACCTGCTGCTTCCAA-3 and 
5-GAATTCATAGCTTCGCACCCA-3; CRTH2, 5-AAAAGGCTCGG-
GAAGGTTAAATG-3 and 5-ACCGGGGAACCAAGAGAGAG-3; CCR8, 
5-GGTCATCCTGGTCCTTGTGG-3 and 5-CAGGGCCAGGTTCA-
AGAGG-3; CCR3, 5-GCAAGCATCTGGACCTGGTC-3 and 5-GGT-
TCATGCAGCAGTGGGA-3; CCL1, 5-TGCAGATCATCACCA-
CAGCC-3 and 5-GTCCACATCTTCCGGCCA-3; CCL18, 5-TGGC-
AGATTCCACAAAAGTTCA-3 and 5-GGATGACACCTGGCTTGGG-3; 
and GAPDH, 5-GAAGGTGAAGGTCGGAGTC-3 and 5-GAAG-
ATGGTGATGGGATTTC-3. Using the comparative Ct method, relative 
gene expression was calculated as 2Ct where Ct = Ct (gene of interest) 
 Ct (normalizer = GAPDH) and the Ct = Ct (sample)  Ct (calibrator = 
mean Ct of normals). Harvested mouse and human macrophages were 
harvested and stored in RLT buffer and purified RNA was isolated using 
the RNeasy kit (QIAGEN). Real-time PCR was performed as above with 
the mouse and human primers described below. Mouse primers: Arg1, 
5-CAGAAGAATGGAAGAGTCAG-3 and 5-CAGATATGCAGGGA-
GTCACC-3; Ym1, 5-TCACAGGTCTGGCAATTCTTCTG-3 and 
macrophages by culturing in the presence of 50 ng/ml m-CSF (PeproTech) 
in C10 media for 7 d in 24- or 12-well plates. Human AAMs were obtained 
by culturing these macrophages in fresh C10 supplemented with 25 ng/ml 
IL-4 (PeproTech), 10 ng/ml IL-10 (Miltenyi Biotec), and 20 ng/ml TNF 
(Miltenyi Biotec) for an additional 24–72 h. Bone marrow cells isolated from 
femurs and tibias were cultured in non–tissue culture–treated 100-mm bacte-
rial culture Petri dishes (Thermo Fisher Scientific) in C10 media supple-
mented with 10 ng/ml murine M-CSF (PeproTech) and fed with fresh media 
on days 4 and 8. Cells were harvested at day 8 and replated in 24- or 12-well 
plates in M-CSF–containing media and stimulated with 20 ng/ml IL-4, 
10 ng/ml IL-10, and 20 ng/ml TNF and harvested after 24 or 72 h.
Quantitation of integrin LFA-1 activation in highly polarized Th2 
cells. Prior to assays, human Th2 cells were activated with 2 µg/ml plate-
bound mAb to CD3 and 1 µg/ml soluble mAb to CD28 for 24 h. Cells were 
then washed, replated, and rested for 4–5 h in low–IL-2 medium before 
assays. For LFA-1 activation assays, cells were washed and stained in 1% human 
serum/RPMI with 10 µg/ml mAb24 (Hycult Biotech) in the presence of 
200 nM CCL18, 200 nM CXCL12, or 50 ng/ml PMA or in the absence of 
stimulation for 30 min at 37°C, washed, and then stained with 1 µg/ml sec-
ondary goat anti–mouse PE for 20 min, washed, fixed, and acquired on a 
FACSCalibur. As a control, CD3/CD28-activated Th2 cells were stained 
with 10 µg/ml mAb24 in the presence of 200 nM CCL18 at 4°C for 30 min, 
followed by secondary antibody staining. As an additional control, Th2 cells 
that were not activated with CD3/CD28 were stimulated with 200 nM 
CCL18 and stained with 10 µg/ml mAb24 antibody at 37°C for 30 min fol-
lowed by secondary antibody staining. CCL18 did not induce m24 epitope 
expression on these resting Th2 cells.
Flow cytometry and intracytoplasmic cytokine staining. For CCR8 
staining, cells were stained with the 433H mAb to human CCR8, which was 
purified from the hybridoma (American Type Culture Collection), followed 
by PE-conjugated goat anti–mouse IgG(H+L) (SouthernBiotech; Islam et al., 
2011). Intracytoplasmic staining was performed using a standard protocol 
(Islam et al., 2011). Briefly, cells were stained with PE-conjugated mAb to 
IL-4 and allophycocyanin-conjugated mAb to IL-5 (BD), or appropriate 
fluorochrome-conjugated IgG1 isotype-control (BD). Cells were acquired 
on a FACSCalibur and analyzed with FlowJo (9.5.2).
Chemotaxis assays. CCR8-transfected cells, untransfected cells, and human 
Th2 cells (2.5 × 104-105 per well) in RPMI containing 0.5% BSA were 
placed on the top of a 96-well ChemoTx chemotaxis apparatus with 5-µm 
pores (NeuroProbe). CCL18, human CCL1, and CXCL12 (R&D Systems) 
were added to the bottom well. For “checkerboard-type” chemotaxis assays, 
CCL18 was added to the top well in varying concentrations. The apparatus 
was incubated at 37°C and 5% CO2 for 3–4 h, and the cells migrating at each 
concentration of chemoattractant were counted using an inverted micro-
scope at the end of the experiment or after fixation with 10% buffered for-
malin. The number of cells migrating at each concentration of chemokine 
was normalized to the number of cells migrating in the presence of medium 
alone (chemokinesis) to calculate the chemotactic index for each leukocyte 
type. PTX (Sigma-Aldrich) or the 433H neutralizing mAb to human CCR8 
was used in some assays (Islam et al., 2011).
Calcium flux assays. CCL18, human CCL1 and CXCL12, or vMIP-I 
(R&D Systems) were used in calcium flux assays. Calcium flux assays were 
performed on a UV laser–equipped 13-color LSR II flow cytometer (BD) as 
previously described (Islam et al., 2011). Indo-1 AM (Molecular Probes) fluor-
escence was analyzed with the UV A detector at 530/30 and UV B detector 
at 440/40 for free and bound probe with Indo-1 (blue) and Indo-1 (violet), 
respectively. Data were analyzed with standardized settings using the calcium 
flux kinetic software analysis platform of FlowJo (8.8).
Receptor binding assays. Binding assays were performed with 100,000 
cells in a total volume of 100 µl binding buffer in 0.65 µm 96-well Durapore 
glass fiber filter plates (EMD Millipore) that were first wetted with binding 
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5-TTTGTCCTTAGGAGGGCTTCCTCG-3; Fizz1, 5-GGTCCCAG-
TGCATATGGATGAGACCATAGA-3 and 5-CACCTCTTCACTCGAG-
GGACAGTTGGCAGC-3; Ccl8, 5-TCTACGCAGTGCTTCTTTGCC-3 
and 5-AAGGGGGATCTTCAGCTTTAGTA-3; Ccl17, 5-CCCATG-
AAGACCTTCACCTC-3 and 5-CATCCCTGGAACACTCCACT-3; 
and Gapdh, 5-GGCAAATTCAACGGCACAGT-3 and 5-AGATGGTG-
ATGGGCTTCCC-3. Human primers: CCL18, 5-GGTGTCATCCTC-
CTAACCAAGAGA-3 and 5-GCTGATGTATTTCTGGACCCACTT-3; 
and CCL17, 5-CCATCGTTTTTGTAACTGTGCAG-3 and 5-TGCAT-
TCTTCACTCTCTTGTTGTTG-3.
Statistical analysis. Statistical analysis was performed using Student’s un-
paired two-tailed t test for means, except where indicated in Fig. 1 e (two-
way ANOVA to assess the effect of multiple concentrations of CCL18 on 
CCL1-induced chemotaxis), Fig. 3 c (two-way ANOVA to compare the 
binding displacement of 125I-CCL18 by multiple concentrations of cold 
CCL18 and cold CCL1 to that induced by the non-CCR8 ligand CCL3), 
and Fig. 5 e (Mann-Whitney U test for nonparametric comparison of means 
among normal controls, patients with inactive EoE, and patients with active 
EoE). Spearman’s correlation coefficients were used for nonparametric test-
ing of statistical dependence between pairs of predefined EoE-associated 
variables. P < 0.05 was considered significant.
Online supplemental material. Table S1 shows a summary of study sub-
jects who underwent endoscopic biopsy after being referred for suspected 
reflux or EoE. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20122842/DC1.
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